Class Action Lawsuit Announced for REGENXBIO Securities

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 2 days ago

0mins

RGNX-1.74%

Should l Buy RGNX?

Source: PRnewswire

Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of REGENXBIO (NASDAQ:RGNX) securities purchasers from February 9, 2022, to January 27, 2026, indicating investor concerns regarding the company's future prospects.
Compensation Structure: Investors joining the lawsuit will not incur any upfront costs through a contingency fee arrangement, which lowers the barrier for participation and may encourage more affected investors to join the action.
Case Background: The lawsuit alleges that REGENXBIO provided false and misleading information regarding the development of its RGX-111 gene therapy, resulting in investor losses when the true facts emerged, highlighting significant deficiencies in the company's disclosure practices.
Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on RGNX

Wall Street analysts forecast RGNX stock price to rise

7 Analyst Rating

7 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.040

Low

19.00

Averages

29.71

High

45.00

Current: 8.040

Low

19.00

Averages

29.71

High

45.00

Morgan Stanley

Overweight

NULL

downgrade

$25 -> $18

2026-02-10

Reason

Morgan Stanley

Price Target

$25 -> $18

AI Analysis

2026-02-10

downgrade

Overweight

NULL

Reason

Morgan Stanley lowered the firm's price target on Regenxbio to $18 from $25 and keeps an Overweight rating on the shares after the FDA has issued a Complete Response Letter relating to RGX-121's BLA in MPS II due to a lack of substantial evidence of effectiveness. The firm, which updated its model to reflect the CRL for RGX-121 and the uncertainty around the potential path forward, tells investors that "the most tangible financial impact" stems from the loss of proceeds from the sale of a potential Priority Review Voucher.

Baird

Brian Skorney

Outperform -> NULL

downgrade

$39 -> $27

2026-02-10

Reason

Baird

Brian Skorney

Price Target

$39 -> $27

2026-02-10

downgrade

Outperform -> NULL

Reason

Baird analyst Brian Skorney lowered the firm's price target on Regenxbio to $27 from $39 and keeps an Outperform rating on the shares. The firm updated its model following the FDA CRL on RGX-121.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RGNX

Unlock Now

About RGNX

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

REGENXBIO Faces Class Action Lawsuit

10 hours agoPRnewswire

Lawsuit Background: Robbins LLP reminds investors of a class action filed on behalf of shareholders who purchased REGENXBIO (NASDAQ:RGNX) securities between February 9, 2022, and January 27, 2026, alleging the company misled investors regarding the viability of its drug candidate RGX-111.
Drug Safety Issues: The complaint claims that while REGENXBIO touted RGX-111's FDA Fast Track designation in 2018 and reported positive clinical trial results, the company was aware of serious safety concerns, including the potential for central nervous system tumors.
FDA Clinical Hold: On January 28, 2026, the FDA placed a clinical hold on RGX-111 after a participant developed an intraventricular CNS tumor, causing REGENXBIO's stock to plummet 17.8% in a single day, from $13.41 to $11.01 per share.
Shareholder Action: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers by April 14, 2026, while those who choose not to participate can remain absent class members eligible for recovery.

REGENXBIO Faces Class Action Lawsuit Over Allegations of Misleading Information

11 hours agoGlobenewswire

Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against REGENXBIO in the U.S. District Court for the Southern District of Maryland on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026, indicating significant legal risks for the company.
Allegation Details: The lawsuit alleges that REGENXBIO misled investors regarding the development of its gene therapy RGX-111 by providing overly optimistic trial success forecasts while concealing critical adverse facts about the trial's safety and efficacy, potentially leading to investor losses.
Stock Price Plunge: Following the FDA's clinical hold on RGX-111, REGENXBIO's stock price plummeted from $13.41 per share on January 27, 2026, to $11.01 on January 28, representing a 17.8% decline in just one day, reflecting strong market concerns about the company's future.
Investor Rights Protection: Affected investors have until April 14, 2026, to apply to be lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to help investors understand their legal rights and potential remedies.

REGENXBIO Faces Securities Litigation Investigation

1 day agoGlobenewswire

Litigation Investigation: Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO for investors who purchased securities between February 9, 2022, and January 27, 2026, indicating possible legal liabilities for the company.
FDA Clinical Hold: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its gene therapies RGX-111 and RGX-121 due to a neoplasm case in a trial participant, leading to decreased investor confidence in product safety.
Significant Stock Drop: Following the FDA announcement, REGENXBIO's stock price fell by $2.40, or 17.9%, closing at $11.01 per share, reflecting market concerns regarding the company's future prospects.
Investor Rights Reminder: Faruqi & Faruqi reminds investors that April 14, 2026, is the deadline to apply as lead plaintiff in the federal securities class action, emphasizing that participation in the legal process may affect their recovery outcomes.